Procter & Gamble (NYSE:PG – Get Free Report) and Kenvue (NYSE:KVUE – Get Free Report) are both large-cap consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Procter & Gamble and Kenvue, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Procter & Gamble | 0 | 11 | 15 | 0 | 2.58 |
| Kenvue | 0 | 10 | 0 | 0 | 2.00 |
Procter & Gamble presently has a consensus target price of $170.57, suggesting a potential downside of 1.30%. Kenvue has a consensus target price of $19.29, suggesting a potential downside of 0.13%. Given Kenvue’s higher possible upside, analysts clearly believe Kenvue is more favorable than Procter & Gamble.
Earnings & Valuation
This table compares Procter & Gamble and Kenvue”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Procter & Gamble | $87.92 billion | 4.56 | $16.05 billion | $6.64 | 26.03 |
| Kenvue | $15.53 billion | 2.39 | $1.47 billion | $0.88 | 21.94 |
Procter & Gamble has higher revenue and earnings than Kenvue. Kenvue is trading at a lower price-to-earnings ratio than Procter & Gamble, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Procter & Gamble and Kenvue’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Procter & Gamble | 18.23% | 31.02% | 12.92% |
| Kenvue | 10.76% | 21.22% | 8.37% |
Volatility and Risk
Procter & Gamble has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Kenvue has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.
Dividends
Procter & Gamble pays an annual dividend of $4.35 per share and has a dividend yield of 2.5%. Kenvue pays an annual dividend of $0.84 per share and has a dividend yield of 4.4%. Procter & Gamble pays out 65.5% of its earnings in the form of a dividend. Kenvue pays out 95.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Procter & Gamble has raised its dividend for 70 consecutive years and Kenvue has raised its dividend for 1 consecutive years.
Insider & Institutional Ownership
65.8% of Procter & Gamble shares are owned by institutional investors. Comparatively, 97.6% of Kenvue shares are owned by institutional investors. 0.2% of Procter & Gamble shares are owned by company insiders. Comparatively, 1.6% of Kenvue shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Procter & Gamble beats Kenvue on 12 of the 17 factors compared between the two stocks.
About Procter & Gamble
The Procter & Gamble Company is a consumer goods company that develops, manufactures and markets products for everyday use. Founded in 1837 by William Procter and James Gamble, the company is headquartered in Cincinnati, Ohio. Its products span beauty, grooming, health care, fabric and home care, and baby, feminine and family care. Well-known brands include Tide, Pampers, Gillette, Pantene, Olay, Oral-B, Crest, Dawn, Charmin and Bounty. Procter & Gamble sells its products in markets around the world through retail stores, e-commerce platforms and other distribution channels.
About Kenvue
Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.
Receive News & Ratings for Procter & Gamble Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procter & Gamble and related companies with MarketBeat.com's FREE daily email newsletter.
